MSD’s Cyril Schiever outlines why vaccine hesitancy is such a threat to global health, the misinformation around vaccines being spread online, and how multi-stakeholder collaboration can help counter this emerging…
Rodrigo Araujo of global organizational consulting firm Korn Ferry outlines what he sees as the leadership profile of the future – agile, digital, self-aware, and able to transform both themselves…
Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry. Biotech [is the] new frontier for US-China tensions…
Puerto Rico’s close-knit pharmaceutical sector is aiming to attract new talent to the industry so as to further increase its global competitiveness. There is a strong, robust ecosystem around…
Egypt has seen a decade of great transformation, from political instability and uncertainty to its current relative stability. Healthcare reform now stands near the top of the government’s agenda and…
Ulrich Neumann of Certara outlines recent developments in the use of real-world evidence (RWE) and the sizeable impact it stands to make on the global biopharma industry. While the…
PharmaBoardroom last reported on Thailand in 2015, meeting country managers from across the healthcare and life sciences value chain. Here, we chart some of their career progressions since then. …
With a strong research base formed around the Karolinska Institute and Uppsala University, Sweden has grown to be one of Europe’s premier biotech hotspots. Several companies spun out of research…
Chip Davis of the Association for Accessible Medicines argues that learning from the European biosimilars approval experience could speed up patient access to these complex drugs in the USA. …
David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in the cell and gene therapy market for investments and deal activities. Background Cell and gene therapies…
PharmaBoardroom recently sat down with Janssen EMEA head Kris Sterkens, who outlined the enduring importance of Europe to the global group, even with the emergence of Asian power markets such…
Pfizer, in an attempt to bolster its oncology portfolio, is set to acquire Array Biopharma for USD 10.6 billion in the second half of 2019. The deal will give Pfizer…
See our Cookie Privacy Policy Here
